Drug Search Results
More Filters [+]

Amfetamine

Alternative Names: amfetamine, amphetamine, adderall, amphetamin, adderall xr, amphetamine salts, adzenys er, adzenys xr-odt, evekeo, dyanavel xr, mydayis, biphetamine 12.5, delcobese, biphetamine 7.5, dyanavel xr, dyanavel xr 15, dyanavel xr 10, dyanavel xr 20, dyanavel xr 5, biphetamine 20
Latest Update: 2024-06-19
Latest Update Note: News Article

Product Description

Amfetamines are powerful psychostimulants, producing increased alertness, wakefulness, insomnia, energy and self-confidence in association with decreased fatigue and appetite as well as enhanced mood, well-being and euphoria. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14871155/)

Mechanisms of Action: ADRA1A Agonist,ADRA2A Agonist,CYP2D6 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Canada | Chile | Israel | United Kingdom | United States

Approved Indications: Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity | Attention Deficit Disorder with Hyperactivity

Known Adverse Events: Tachycardia | Abdominal Pain | Dizziness | Headache | Pain Unspecified | Insomnia | Asthenia | Diarrhea | Weight Loss | Urinary Tract Infections | Attention Deficit Disorder with Hyperactivity | Anorexia

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Amfetamine

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Attention Deficit Disorder with Hyperactivity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TRI108-ADD-600

P2

Completed

Attention Deficit Disorder with Hyperactivity

2021-10-15

32%

Recent News Events